Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.58 |
| ▸ | BRD9 | Q9H8M2 | 12/20 | 0.52 |
| ▸ | BRD4 | O60885 | 4/20 | 0.52 |
| ▸ | BRPF1 | P55201 | 3/20 | 0.52 |
| ▸ | BRD7 | Q9NPI1 | 2/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
| ▸ | DRD3 | P35462 | 3/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL414567 | 0.86 | NCF1 (0.58) | NCF1BRD9BRD4BRPF1BRD7 | |
| SCHEMBL5161795 | 0.82 | NCF1 (0.61) | NCF1BRD9BRD4BRPF1BRD7 | |
| SCHEMBL14355870 | 0.82 | NCF1 (0.57) | NCF1BRD9BRD4BRPF1BRD7 | |
| SCHEMBL8361520 | 0.82 | DRD2 (0.72) | NCF1BRD9BRD4BRPF1BRD7 | |
| SCHEMBL14355761 | 0.80 | SETDB1 (0.56) | NCF1BRD9BRD4BRPF1BRD7 | |
| SCHEMBL14355759 | 0.79 | NCF1 (0.61) | NCF1BRD9BRD4BRPF1BRD7 | |
| SCHEMBL12368809 | 0.79 | NCF1 (0.61) | NCF1BRD9BRD4BRPF1BRD7 | |
| SCHEMBL110927 | 0.79 | NCF1 (0.87) | NCF1BRD9BRD4BRPF1BRD7 | |
| SCHEMBL29505669 | 0.79 | NCF1 (0.87) | NCF1BRD9BRD4BRPF1BRD7 | |
| SCHEMBL14355767 | 0.79 | DRD2 (0.51) | NCF1BRD9BRD4BRPF1BRD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597699-B2 | MEK inhibitors and methods of their use | EXELIXIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| CN-109053523-B | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-111643496-A | Methods of using MEK inhibitors | 埃克塞利希斯股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| US-20200283383-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20200031770-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS, INC. | 2020-01-30 | — | — | US | disclosed |
| CN-110668988-A | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2020-01-10 | — | — | CN | disclosed |
| US-20190144382-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2019-05-16 | — | — | US | disclosed |
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20170166523-A9 | MEK Inhibitors And Methods Of Their Use | EXELIXIS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20150141399-A1 | MEK Inhibitors And Methods Of Their Use | EXELIXIS INC (US) | 2015-05-21 | — | — | US | disclosed |
| US-7999006-B2 | Anticancer agents; mitogen-activated protein kinases (MEK) | EXELIXIS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| EP-1934174-B1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | EXELIXIS INC (US) | 2011-04-06 | — | — | EP | disclosed |
| US-7915250-B2 | Azetidines as MEK inhibitors for the treatment of proliferative diseases | EXELIXIS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100249096-A1 | anticarcinogenic agent; 1-({4-[(2-fluoro-4-iodophenyl)amino]-3-thienyl}carbonyl)azetidin-3-amine | EXELIXIS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7803839-B2 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| EP-2101759-A1 | METHODS OF USING MEK INHIBITORS | Exelixis, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20090156576-A1 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS INC. (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008124085-A2 | METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
| WO-2008076415-A1 | METHODS OF USING MEK INHIBITORS | EXELIXIS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166523-A9 | MEK Inhibitors And Methods Of Their Use | BRAF, NRAS, MAP3K1 | NCF1 1262/4885BRD9 2168/4885BRD4 1077/4885 |
| US-20200283383-A1 | MEK Inhibitors and Methods of Their Use | BRAF, NRAS, MAP3K20 | NCF1 1396/4885BRD9 2122/4885BRD4 988/4885 |
| US-20150141399-A1 | MEK Inhibitors And Methods Of Their Use | BRAF, NRAS, MAP3K1 | NCF1 1262/4885BRD9 2168/4885BRD4 1077/4885 |
| US-20100249096-A1 | anticarcinogenic agent; 1-({4-[(2-fluoro-4-iodophenyl)amino]-3-thienyl}carbonyl)azetidin-3-amine | NRAS, BRAF, KRAS | NCF1 464/4885BRD9 659/4885BRD4 742/4885 |
| US-20090156576-A1 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | NRAS, BRAF, KRAS | NCF1 605/4885BRD9 805/4885BRD4 1227/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | NCF1 1190/4885BRD9 1788/4885BRD4 844/4885 |
| US-20190144382-A1 | MEK Inhibitors and Methods of Their Use | BRAF, NRAS, MAP3K20 | NCF1 1396/4885BRD9 2122/4885BRD4 988/4885 |
| US-11597699-B2 | MEK inhibitors and methods of their use | BRAF, NRAS, MAP3K20 | NCF1 1396/4885BRD9 2122/4885BRD4 988/4885 |
| US-20200031770-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | BRAF, NRAS, MAP3K20 | NCF1 1396/4885BRD9 2122/4885BRD4 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.